

CORRECTION

Open Access



Correction to: Treatment duration with immune-based therapies in Cancer: an enigma

Shanta Bantia^{1*} and Nirmal Choradia²

**Correction to: *Journal for ImmunoTherapy of Cancer*
(2018) 6:143
Doi: 10.1186/s40425-018-0465-0**

Following publication of the original article [1], the authors reported an error in the typesetting of their article. The first section of the main text was mistakenly included in the abstract. This section begins with the sentence “Chemotherapy and immune-based therapies provide antitumor effects through completely different mechanisms” and ends with the following sentence:

“In exploring treatment duration with immune based therapies, we need to answer the following: (1) does indefinite treatment with immune based therapies exhaust the immune system counteracting its own mechanism of action leading to tumor progression and (2) how can clinical trials be designed to identify the optimal duration of immunebased therapy that prevents immune cell exhaustion but supports anti-tumor immunity.”

The published apologizes for any inconvenience caused by this error.

Author details

¹Nitor Therapeutics, 689, Highland Lakes Cove, Birmingham AL-35242, USA.

²Palo Alto Veterans Affairs Hospital, 3801 Miranda Ave, Palo Alto, CA 94304, USA.

Received: 17 December 2018

Published online: 26 February 2019

Reference

1. Bantia and Choradia. *Journal for ImmunoTherapy of Cancer*. 2018;6:143. <https://doi.org/10.1186/s40425-018-0465-0>.

* Correspondence: sbantia@nitortherapeutics.com

¹Nitor Therapeutics, 689, Highland Lakes Cove, Birmingham AL-35242, USA

Full list of author information is available at the end of the article

